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ABSTRACT
Sepsis in pregnancy and the puerperium remains a significant cause of maternal mortality and morbidity worldwide. Major mor-
bidity arising as a result of obstetric sepsis includes fetal demise, organ failure, chronic pelvic inflammatory disease, chronic pelvic
pain, bilateral tubal occlusion and infertility. Early recognition and timely response are key to ensuring good outcome. This review
examines the clinical problem of sepsis in obstetrics and the role of the anaesthetist in the management of this condition.
c 2011 Elsevier Ltd. All rights reserved.
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In the most recent Confidential Enquiries into Maternal
Deaths in the UK, sepsis was the leading cause of direct
maternal death, and the maternal mortality rate from
sepsis has almost tripled in the last 25 years.1 World-
wide, sepsis accounts for 15% of maternal deaths.2 The
Scottish Confidential Audit of Severe Maternal Morbid-
ity showed a rate of septicaemic shock of 0.11 per 1000
maternities in the 2006–2008 triennium.3 In a retrospec-
tive analysis of ‘near-miss cases’ from a tertiary mater-
nity unit in the United States, sepsis was responsible
for 15% of cases.4 Sepsis in the obstetric population
poses significant challenges: the physiological changes
of pregnancy may mask the clinical signs of sepsis and
when it occurs in the antenatal period maternal deterio-
ration can quickly lead to fetal compromise. Early rec-
ognition and diagnosis with rapidly instituted therapy
are key to ensuring a good outcome.
History
During the 18th, 19th and 20th centuries, sepsis was the
leading cause of maternal death in England and Wales.
Between the years 1847 and 1903 there were 93342 re-
corded maternal deaths from puerperal fever.5,6 Accu-
racy of record keeping improved after puerperal fever
became a notifiable disease in 1899 and it remained so
until the late 1960s. It was long recognised that puer-
peral fever occurred in epidemics in ‘lying-in’ (mater-
nity) hospitals. In 1867 Florence Nightingale wasAccepted November 2011
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King’s College Hospital only five years previously, be-
cause of excessive rates of puerperal fever.
The earliest recognition that puerperal fever was con-
tagious came from Alexander Gordon’s Treatise on the
Epidemic of Puerperal Fever in Aberdeen published in
1795.7 In America this observation was later supported
by Oliver Wendell Holmes’ 1843 paper The Contagious-
ness of Puerperal Fever.8 A significant contribution was
made by Ignaz Semmelweis working at the Vienna
Maternity Hospital. He recognised that medical stu-
dents who were attending post-mortems, and then
labouring women, were transmitting infection. In 1847
he introduced hand washing using disinfectant, after
which there was a dramatic fall in the incidence of puer-
peral fever from 18% to 1.27%.9,10
In the early part of the last century in the UK there
was growing concern at the number of women who died
in association with childbirth. A government-commis-
sioned investigation into maternal deaths in England
published in 1937, found that sepsis accounted for
39% of all deaths.11 In 1935 Leonard Colebrook, a phy-
sician working at Queen Charlotte’s Hospital in Lon-
don, gave the first sulphonamide, Prontosil, to a
woman who was severely ill with puerperal sepsis and
she made a full recovery.5 This event heralded the intro-
duction of antibiotics in the treatment of puerperal sep-
sis, and by the mid-1940s penicillin had become
commercially available. Thus by the time of the first for-
mal confidential enquiry report into maternal death,
published in 1957, maternal deaths from sepsis had al-
ready started to decline sharply (Fig. 1).12 Over the fol-
lowing decades this decline was associated with other
causes of maternal death coming to the fore in the devel-
oped world. However, in the UK sepsis has recently ta-
Fig. 1 Trends in maternal mortality from genital tract sepsis;
England & Wales 1952–1984, UK 1985–2008.
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again the leading cause of maternal death.1 In the devel-
oping world there is significant regional variation in
many of the leading causes of maternal death. In Africa,
haemorrhage is the leading cause of death, whereas in
Latin America it is hypertensive disease. In contrast,
deaths from sepsis do not show this variation and are
consistently a significant cause of maternal mortality
in all parts of the developing world.13
Definitions
The term sepsis includes illness that ranges from minor
signs and symptoms through to organ dysfunction and
shock. There is currently no universally accepted defini-
tion of sepsis in obstetric practice. The term puerperal
sepsis is still used to describe sepsis occurring after deliv-
ery and the World Health Organisation (WHO) has de-Table 1 American College of Chest Physicians and Society
Systemic inflammatory response syndrome
Systemic inflammatory response syndrome (SIRS) is a widespread
This syndrome is clinically recognized by the presence of two o
 Temperature >38C or <36C
 Heart rate >90 beats/min
 Respiratory rate >20 breaths/min or PaCO2 < 32 mmHg
 White blood cells >12 · 109/dL or <4 · 109/dL or >10% immatu
Sepsis
Sepsis is the systemic response to infection. Thus in sepsis, clinica
evidence of infection
Severe sepsis
Sepsis is considered severe when associated with organ dysfunctio
hypoperfusion may include, but are not limited to, lactic acidos
Septic shock
Septic shock is sepsis with hypotension despite adequate fluid resu
acidosis, oliguria, or an acute alteration in mental status. Patient
be hypotensive at the time that perfusion abnormalities are presfined it as ‘‘infection of the genital tract occurring at any
time between rupture of membranes or labour, and the




 abnormal vaginal discharge
 abnormal smell of discharge
 delay in postpartum reduction of size of uterus.14
A widely used definition for sepsis in the non-preg-
nant patient has come from the American College of
Chest Physicians and the Society of Critical Care Med-
icine (Table 1).15 This was modified in 2001 by the Inter-
national Sepsis Definition Forum to include alterations
in physiological variables, in order to convey more accu-
rately the clinical experience. However, because of the
physiological changes of pregnancy and particularly
those around the time of delivery, this definition lacks
validity in obstetric patients.
There are various other reasons that add to the diffi-
culty of defining sepsis in obstetric practice. Sepsis may
arise in an obstetric patient at any time: before delivery,
during labour or in the postnatal period. In addition,
sepsis in obstetric patients can arise from many sources
and is not limited to infections arising from the genital
tract. This difficulty in reaching a definition is demon-
strated by the organisation of cases in the UK Confiden-
tial Enquiry Reports. Deaths due to Group A beta-
haemolytic Streptococcus pyogenes, as well as other
infections related to pregnancy or delivery, are classified
as direct deaths, whereas deaths from infections unre-
lated to the genital tract such as pneumococcal meningi-
tis and human immunodeficiency virus (HIV) areof Critical Care Medicine definitions related to sepsis
inflammatory response to a variety of severe clinical insults.
r more of the following:
re (band) forms
l signs describing SIRS are present together with definitive
n, hypoperfusion or hypotension. Manifestations of
is, oliguria, or an acute alteration in mental status
scitation. It includes perfusion abnormalities such as lactic
s receiving inotropic or vasopressor agents may not necessarily
ent
Table 3 Risk factors for sepsis in obstetrics
Obstetric factors
58 Sepsis in obstetricsclassified as indirect maternal deaths. A new pathologi-
cal classification has been proposed for future confiden-
tial enquiries.1
The WHO Technical Working Group has introduced
the term puerperal infections as a more general term
than puerperal sepsis, to include not only infections re-
lated to genital tract sepsis, but also all extra-genital
infections and incidental infections (Table 2).
The immune system in pregnancy
Pregnancy has traditionally been viewed as an immuno-
compromised state arising as a result of the necessity not
to reject the fetus immunologically, and therefore plac-
ing the mother at increased risk of infectious diseases.
However, there is now a wealth of evidence to suggest
that rather than being a immunosuppressed state, preg-
nancy presents a modified immune state whereby there
may be contrasting responses to different infections, re-
sponses that are also determined by the stage of preg-
nancy.16,17 From a logical and evolutionary
perspective a successful pregnancy is key to the conser-
vation of the species and it has been suggested by Wilson
that pregnancy is a ‘‘paradoxical immune state where
foreign tissue is not only tolerated but nurtured’’.18
A competent immune response is essential to protect
the mother directly and the fetus indirectly. The immune
response depends on either cell-mediated immunity
(particularly T lymphocytes) or the humoral response
(antibodies secreted by B lymphocytes and plasma cells).
During pregnancy progesterone and oestrogen reduce T
cell proliferation and there is consequently a reduction
in cell-mediated immunity which might otherwise prove
harmful to the fetus. The maternal immune system is
therefore biased towards humoral immunity.19 Coupled
with this is the developing active immune system of the
fetus, which will also modify the maternal response to
infection.
Three distinct immunological phases have been de-
scribed in pregnancy, roughly corresponding with the
first, second and third trimesters, and associated with
dramatic changes in cytokine levels.17 The combined ef-Table 2 World Health Organisation definition of puer-
peral infections
Infections of the genitourinary system related to labour,
delivery and the puerperium:
Infections related to the uterus and its associated structures
(endometritis)
Infections related to the urinary tract




e.g. malaria, respiratory tract infectionsfect of these interactions serves to explain why in preg-
nancy women may exhibit a diverse response to
infection, depending not only on the infecting organism
but also on the stage of the pregnancy, e.g. pregnant wo-
men living in malarial endemic areas are more suscepti-
ble to malarial infection in the first-half of pregnancy
and this susceptibility decreases as the pregnancy
progresses.20
Risk factors and causes of sepsis in obstetrics
Sepsis can arise at any time during pregnancy and the
puerperium, and may develop as a result of bacteraemia
(although bacteraemia does not always lead to sepsis),
or as a result of local infection. Risk factors for maternal
sepsis may be divided into intrinsic patient factors and
obstetric factors (Table 3). In addition, women from
poor socio-economic backgrounds are at greater risk
of sepsis although the mechanisms are unclear.21
Although none of the women who died from sepsis in
the 2006–2008 UK Centre for Maternal and Child
Enquiries (CMACE) report were obese, obesity remains
a significant risk factor for obstetric sepsis; in the 2003–
2005 report the majority of the women who died from
sepsis were obese.22
In patients with sickle cell disease functional asplenia
results in increased susceptibility to bacterial infection;
three women whose deaths were reported in the 2006–
2008 CMACE report were noted to have either sickle
cell disease or sickle trait. An analysis of maternal out-
comes in almost 18000 deliveries by women with sickle
cell disease found that there was a significantly higher
rate of sepsis in this group (odds ratio 6.8) compared
to women without sickle cell disease.23 This risk may
be further compounded by the presence of anaemia.24
Sickle cell trait has in the past been viewed as a benign
carrier state but there is now evidence that it can be
viewed as an intermediate disease phenotype.25 A study Amniocentesis, and other invasive intrauterine procedures
 Cervical suture
 Prolonged rupture of membranes
 Prolonged labour with multiple (>5) vaginal examinations
 Vaginal trauma
 Caesarean section
 Retained products of conception after miscarriage or delivery
Patient factors
 Obesity




 History of pelvic infection
 History of Group B streptococcal infection
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riers found an increased risk of bacteriuria in women
with sickle sell trait.26
The causes of sepsis in obstetrics may be divided into
obstetric and other causes (Table 4). In early pregnancy
the commonest causes of sepsis are septic abortion or
termination of pregnancy. Caesarean section endometri-
tis used to be a major cause of postpartum infection with
the incidence of sepsis following operative delivery once
being as high as 36%.27 Women undergoing caesarean
section still have a five- to 20-fold greater risk for infec-
tion and infectious morbidity compared with a vaginal
birth.28 A cohort study from Denmark of over 32000
women compared the risk of postpartum infections
within 30 days of delivery, following vaginal delivery,
or emergency or elective caesarean section. The risk of
postpartum infection for all women delivered by caesar-
ean section was 7.6%, versus 1.6% for women who had a
vaginal delivery (adjusted odds ratio 4.71).29 Routine
antibiotic prophylaxis at caesarean section was in place
during the study period and therefore even with this pre-
caution, infection was five times more likely in women
who delivered by caesarean section rather than vaginal
delivery. The authors also found a nearly 50% higher
risk of postpartum wound infection after emergency
caesarean section compared to elective caesarean section
(odds ratio 1.49).
Smaill and Gyte28 reviewed 86 studies involving over
13000 women. They found prophylactic antibiotics in
women undergoing caesarean section substantially re-
duced the incidence of febrile morbidity, wound infec-
tion, endometritis and serious maternal infectious
complications. The mandatory use of prophylactic anti-
biotics at caesarean section has been a recommendation
for some time. However, the timing of prophylactic anti-






 Wound infection following caesarean section/episiotomy/
vaginal tear
Non-genital tract causes
 Lower urinary tract infection
 Pyelonephritis
 Breast infection – abscess/mastitis
 Septic pelvic thrombophlebitis
Non-obstetric causes
 Human immunodeficiency virus
 Pneumonia
 Tuberculosis
 Malariasion.30 Largely because of concerns about neonatal
infection, the prevailing UK practice has been to use
narrow-range antibiotics after cord clamping, compared
to the practice of broad-spectrum pre-incision antibiot-
ics which is standard in non-obstetric surgery. A recent
meta-analysis suggests the latter approach may be more
effective in reducing infections after caesarean section,
without any detrimental effect on the neonate.31 The
American College of Obstetricians and Gynecologists
recommends this strategy32 and in the UK the recently
published National Institute for Clinical Excellence Cae-
sarean Section Guideline Update has also made similar
recommendations.33 The appropriate and optimal anti-
biotic for prophylaxis also remains unclear.34 A Cochra-
ne review found there was no conclusive evidence of any
outcome difference between cephalosporins and penicil-
lins in regard to maternal sepsis, endometritis, fever,
wound infection, urinary tract infection and adverse
effects.35
It has been estimated that after vaginal delivery mas-
titis and urinary tract infections are the commonest
causes of infection.36 Mastitis affects up to 20% of post-
partum women but is comparatively rare as a cause of
postpartum sepsis.37 As a result of the physiological
and anatomical changes of pregnancy within the urinary
tract there is increased susceptibility to urinary tract
infection and urosepsis. There is renal pelvic and ure-
teric dilatation secondary to mechanical obstruction by
the gravid uterus. Progesterone-induced smooth muscle
relaxation leads to decreased peristalsis of the ureters,
increased bladder capacity and urinary stasis. Asymp-
tomatic bacteriuria has an incidence in pregnancy of be-
tween 4–6% but it has been estimated that if left
untreated as many as 20–40% will go on to develop
pyelonephritis.38,39 After delivery the prevalence of uri-
nary tract infections remains significant at around 2–
4%. The presence of a urinary catheter in association
with caesarean delivery and/or neuraxial analgesia in-
creases the risk.40
Microbiology
The genitourinary tract is colonised with a wide variety
of organisms; however, not all of these cause infection
and sepsis. Pregnant women who develop sepsis are very
likely to be infected with more than one organism. Anal-
ysis of the microbiological causes of deaths from sepsis
(direct and indirect) over the last 20 years of the UK
Confidential Enquiry is shown in Table 5.
Historically, although they were not characterised
serologically by Rebecca Lancefield until 1933, it seems
likely that Group A streptococcus was the predominant
cause of obstetric sepsis in the first-half of the 20th cen-
tury.6,9 Outbreaks were frequently described, particu-
larly when scarlet fever was also prevalent. In the
latter part of the 20th century factors such as improved
Table 5 Microbiological causes of maternal death identified in UK Confidential Enquiries 1991–1993 to 2006–2008
1991–1993 1994–1996 1997–1999 2000–2002 2003–2005 2006–2008 Total
b haemolytic streptococcus
Lancefield group A
1 7 3 3 8 13 35
Escherichia coli 2 3 6 2 7 5 25
Streptococcus pneumoniae 3 4 2 5 3 17
Human immunodeficiency virus 1 4 5 2 12
Staphylococcus aureus 1 3 2 4 10
Streptococcus unspecified 5 3 8
Clostridium species 1 1 1 1 1 5
b haemolytic streptococcus
Lancefield group B
2 2 1 5
Tuberculosis 4 2 6
Pseudomonas 1 3 4
Proteus species 2 2 4
Meningococcus 1 1 1 3
Toxoplasmosis 2 1 3
Enterococcus faecalis 1 1 2










Citrobacter kosseri 1 1
Fusobacterium necrophorum 1 1
Bacteroides melaminogenicus 1 1
Data from direct and indirect causes combined for each triennium. Number of deaths may not equal actual number of deaths from reports as full
microbiological data not always available.
60 Sepsis in obstetricsantiseptic techniques, the use of antibiotics and an in-
crease in natural immunity lead to a decline in the viru-
lence of this organism. Gram-negative organisms such
as Escherichia coli then became more common sources
of infection. However, over the past 20 years gram-posi-
tive organisms, and in particular group A streptococcal
infections, have again become predominant. This is con-
sistent with the pattern of group A streptococcal infec-
tions in the general population of the developed world,
where there has been a dramatic rise in the number of
such infections.41,42 In the most recent UK CMACE Re-
port, group A streptococcal infections accounted for 13
of the 29 deaths. In this report the majority of the deaths
were noted to occur between December and April, and
in many of those who died there was a history of a re-
cent upper respiratory tract infection and/or of contact
with young children. Group A streptococcal upper
respiratory tract infections are most common during
winter and early spring. In contrast group A streptococ-
cus as a cause of skin infections is seen more frequently
during the summer, when the skin is exposed and abra-
sions and insect bites are more likely to occur.
In the developing world there are more limited data
on the specific microbiological causes of obstetric sepsis.
Available evidence suggests a similar pattern of bacterialcauses to that in the developed world.43 However, in re-
cent times the HIV/AIDS pandemic has undoubtedly
been the most important factor with regard to sepsis-re-
lated maternal morbidity and mortality in the develop-
ing world. A major WHO analysis assessing progress
towards the Millennium Development Goal of reducing
maternal mortality, found that in 2008 there were an
estimated 342900 maternal deaths worldwide from all
causes, a 34% decline from 1980.44 It is estimated that
HIV accounted for 61400 of these deaths. The impact
of this disease was greatest in sub-Saharan Africa, where
WHO estimates for 2008 suggest that without HIV/
AIDS related deaths, the maternal mortality ratio for
sub-Saharan Africa would have been 580 maternal
deaths per 100000 live births instead of the actual figure
of 640.45
Pregnant women with HIV/AIDS are more suscepti-
ble to sepsis and post-surgical complications. Many
opportunistic infections associated with HIV/AIDS
may complicate pregnancy and cause maternal mortal-
ity.46 Pneumocystis jirovecii (previously carinii) pneu-
monia has a more aggressive course during pregnancy,
with an increase in both morbidity and mortality.47
The South African Confidential Enquiry into Maternal
Deaths, Saving Mothers, found that bacterial pneumo-
D.N. Lucas et al. 61nias, bacterial sepsis, atypical pneumonia, cryptococcal
meningitis, and tuberculosis (TB) are common co-mor-
bid conditions associated with HIV/AIDS, and may be
the primary causes of maternal death in that country.48
Worldwide the most significant infection contributing to
maternal mortality in HIV-infected women is TB. It ac-
counts for about 700000 deaths annually in women of
reproductive age,49 and is by far the most common
opportunistic infection associated with HIV in the devel-
oping world. A five-year review of maternal mortality at
a tertiary referral centre in Johannesburg found that
mortality in HIV-infected women was 6.2 times greater
than in HIV-negative women and that 31% of HIV-re-
lated deaths were due to TB.50
Postnatal care is often poor in African countries, and
puerperal sepsis is a major cause of maternal mortal-
ity.51 It has been suggested that the impact of puerperal
sepsis could be significantly reduced if, following deliv-
ery, women were to remain in hospital for at least 24
h, and/or improved arrangements were put in place
for postnatal follow-up. Clinical experience suggests
that HIV-infected women may be clinically well at the
time of early discharge, only to be re-admitted with flor-
id sepsis 7–10 days after delivery.48
Clinical presentation and diagnosis
Sepsis is a clinical diagnosis and microbiological investi-
gations may be negative. The onset of sepsis may be
insidious and non-specific, particularly given the physio-
logical changes of pregnancy, labour and the puerpe-
rium. Diagnosis can therefore be difficult, especially in
the early stages. Conversely the disease process can be
fulminant, overwhelming and rapidly fatal.52–54 The cli-
nician must often rely on a high index of clinical suspi-








 Shortness of breath
 Wound infection
Signs
 Pyrexia or hypotheremia, <36C
 Early pregnancy loss/abnormal fetal heart rate/death in utero
 Tachycardia >100 beats/min
 Tachypnoea >20 breaths/min
 Elevated white cell count and neutrophilia or low white cell cou
 Rising C-reactive protein (CRP)
 Lactic acidosis
 Signs of organ decompensation: hypoxaemia; hypotension; coolinfection, such as those colonised with Group B strepto-
coccus, should be identified early in pregnancy.
Initially infection may present with localised symp-
toms and signs; the presenting features vary depend-
ing on the source of infection (Table 6) and a
careful clinical history may help clarify the source.
Maternal infection can rapidly affect the fetus; the
uteroplacental circulation does not exhibit autoregula-
tion, so that fetal perfusion and oxygenation is
dependent on maternal oxygenation and cardiovascu-
lar stability. Thus the septic woman may present with
an abnormal fetal heart rate pattern or intrauterine
fetal death.
Women will invariably experience some degree of
pain following caesarean section or significant vaginal
tears. However, the presence of constant, severe abdom-
inal or perineal pain, poorly responsive to analgesics and
disproportionate to that which would be anticipated, is
a cause for concern, particularly when it is associated
with diarrhoea, and sepsis must then always be consid-
ered in the differential diagnosis.1 When mastitis that
does not respond to conservative management within
24 h, and the woman is becoming systemically unwell,
then the breasts must be considered as a possible source
of sepsis.
The onset of sepsis is characterised by a hyperdy-
namic circulation, reduced systemic vascular resistance
secondary to arterial vasodilatation, and increased respi-
ratory rate in association with the development of
anaerobic metabolism and lactic acidosis. Therefore
when sepsis develops not only can diagnosis be made
more difficult because of the physiological changes of
pregnancy, but in addition the combined effect of path-
ological processes superimposed on a state of increased




 Sickle cell crisis
 Atonic uterus precipitating postpartum haemorrhage
 Mastitis
 Vaginal discharge – profuse and/or malodorous
nt/neutropenia
extremities; reduced capillary refill; oliguria
62 Sepsis in obstetricsPyrexia is common in sepsis but normothermia may
also be present. Hypothermia is a particularly significant
finding. Swinging pyrexia suggests a persistent source of
infection or inadequate treatment.1 Although an ele-
vated white cell count is commonly associated with sep-
sis, pregnancy also leads to an increase in white cell
count, particularly during labour. After delivery the
white cell count usually decreases to pre-pregnancy lev-
els within a week; a white cell count that fails to decrease
to normal levels or conversely decreases rapidly or be-
comes <4 x 109/L may indicate severe infection. One
of the most sensitive and earliest clinical signs of sepsis
is tachypnoea which arises as a result of pyrexia, lactic
acidosis or cytokine-mediated effects on the respiratory
centre. The overlapping physiological changes of preg-
nancy and clinical features of sepsis will often pose diag-
nostic difficulty and the existence of a suitable
biomarker in this context would be particularly useful.
In the intensive care community there has been signifi-
cant interest in the use of biomarkers to help establish
a diagnosis of sepsis. Much of this discussion has fo-
cused on procalcitonin, a peptide precursor of the hor-
mone calcitonin and is produced by the parafollicular
cells of the thyroid and the neuroendocrine cells of the
lung and the intestine. Procalcitonin levels rise specifi-
cally in the presence of bacterial but not viral or fungal
sepsis.55 Therefore laboratory measurement of procalci-
tonin levels can potentially assist with diagnosis. How-
ever, meta-analyses have produced conflicting results
on whether procalcitonin is an effective and useful sepsis
biomarker.56,57 A recent comprehensive review states
that clinical judgement should remain the cornerstone
of clinical decision-making. A more encouraging role
for procalcitonin is its measurement to guide duration
of antibiotic therapy.58
Management and the Surviving Sepsis
Campaign
Management of the septic pregnant patient follows the
same principles as that of any septic patient: resuscita-
tion, identification and treatment of the source of sep-
sis, management of complications such as hypotension
and tissue hypoxia, and the application of organ pro-
tection strategies. The management of sepsis arising in
the antenatal period is complicated by the presence of
the fetus; in this situation maternal resuscitation is key
to ensuring fetal well-being,59 and attempting early
delivery in women with cardiovascular compromise
due to sepsis may increase maternal and fetal mortal-
ity.60 The only exception is when intrauterine infection
is suspected as the source of sepsis.61
Early recognition of the obstetric patient with sep-
sis is key to ensuring optimal outcome. As noted pre-
viously, the physiological changes of pregnancy can
make early detection difficult and at the same timeexacerbate the course of sepsis in an obstetric patient.
The use of early warning scores was a recommenda-
tion in the 2003–2005 UK Confidential Enquiries into
Maternal Deaths.22 Clear evidence of outcome benefit
is, however, lacking, with one major study on the use
of early warning scores and medical response teams in
the non-obstetric hospital population failing to dem-
onstrate a reduction in mortality, though this has been
attributed to a possible lack of sensitivity in the crite-
ria used for triggering clinical calls.62 The importance
of developing maternity early warning scores with
appropriately sensitive parameters for use in obstetric
patients has been emphasised by a recent retrospective
review.63
Recommendations from the Royal College of
Obstetricians and Gynaecologists (RCOG) are that
sepsis should be managed in accordance with the Sur-
viving Sepsis Campaign guidelines.64 This campaign, a
collaboration between the European Society of Inten-
sive Care Medicine, the Society of Critical Care Med-
icine and the International Sepsis Forum, was
launched as a major international health initiative in
2002.65 It aimed to improve outcome in sepsis and
advocated a standardised bundle-based approach for
management of the (non-pregnant) critically-ill septic
patient. A clinical-care bundle is a set of interventions,
usually no more than five, that when grouped and
implemented together lead to better outcomes with a
greater impact than if performed individually. The ele-
ments in a bundle are ideally based on high quality or
level-one evidence such as systematic reviews of multi-
ple well-designed randomized controlled trials. In clin-
ical practice, the application of these elements may
not always be done consistently, leading to variations
in patient care, so a bundle aims to tie the care ele-
ments together into a cohesive unit that must be
strictly adhered to for every patient, every time. Lastly
all the components of a clinical-care bundle must be
completed in a specified time period and place (‘the
golden hour.’) Compliance is measured in an ‘all or
none’ approach.66
The Surviving Sepsis Campaign guidelines described
two clinical-care bundles - the resuscitation bundle (to
be accomplished as soon as possible) and the manage-
ment bundle. The RCOG advocates the use of these in
obstetrics.64
The following care bundle should be applied immedi-
ately where possible or within six hours and has been
shown to significantly improve survival rates67
1. Measure serum lactate.
2. Obtain blood cultures/swab culture before antibiotic
administration.
3. Administer broad-spectrum antibiotic(s) within the
first hour of recognition of severe sepsis and septic
shock according to local protocol
D.N. Lucas et al. 634. In the event of hypotension and/or lactate >4 mmol/L:
(a) deliver an initial minimum of 20 mL/kg of crys-
talloid or colloid
(b) once adequate volume replacement has been
achieved, a vasopressor (e.g. norepinephrine,
epinephrine) and/or an inotrope (e.g. dobuta-
mine) may be used to maintain mean arterial
pressure over 65 mmHg.
5. Further management consists of:
(a) In the event of ongoing hypotension despite fl-
uid resuscitation (septic shock) and/or lactate
>4 mmol/L:
(i) achieve a central venous pressure of at l-
east 8 mmHg (or over 12 mmHg if the
woman is mechanically ventilated) with
further fluid replacement
(ii) consider steroids.
(b) Maintain oxygen saturation with facial oxygen.
Consider transfusion if haemoglobin is <7 g/
dL.
Antibiotic therapy via the intravenous route and in
high therapeutic doses should be started as early as pos-
sible, and preferably within one hour. There is over-
whelming evidence that delay in starting antibiotics is
associated with increased mortality,68 and this has con-
sistently been cited as an area of substandard care in
successive UK confidential enquiries. Causes of delay in-
clude errors in administration, prescription errors, pa-
tients awaiting senior review and patients being
transferred between departments; strenuous efforts must
be made to avoid such delays.69 Relevant swabs and cul-
tures should be taken before antibiotic therapy is started
but should not delay treatment. Where applicable these
should include placental and neonatal swabs, as well asTable 7 Suggested intravenous antibiotic therapy in obstetr
Where the organism is unknown and the woman is not critically i
 Co-amoxiclav 1.2 g 8-hourly or cefuroxime 1.5 g 8-hourly or cefot
hourly
 In cases of allergy to penicillin and cephalosporins, use clarithrom
or 6-hourly plus gentamicin to give Gram-negative cover, while
In severe sepsis or septic shock:
 Piperacillin–tazobactam 4.5 g 8-hourly or ciprofloxacin 600 mg 12
8 hoursa
 A carbapenem such as meropenem 500 mg to 1 g 8-hourly +/
 Metronidazole 500 mg 8-hourly may be considered to provide a
 If Group A streptococcal infection is suspected, clindamycin 600
than penicillins
If there are risk factors for MRSA septicaemia, add teicoplanin 10
linezolid 600 mg 12-hourly
MRSA, methicillin-resistant staphylococcus aureus.
a Gentamicin is more commonly given as a once daily dose because of incbreast milk culture in the presence of mastitis. Broad-
spectrum antibiotics should be used initially and two
or more agents are likely to be needed.70,71 Urgent
microbiological advice should be sought as soon as pos-
sible but should not delay starting antibiotics. The phys-
iological changes of pregnancy, including the increased
volume of distribution, which can also be increased in
sepsis, can have an effect on the pharmacodynamic
and pharmacokinetic profile of the drug. Some women
may have impaired renal or hepatic function and serum
drug levels may need to be monitored to ensure correct
dosage. However the appropriate loading dose when
starting antibiotic therapy is independent of the pa-
tient’s renal function and the initial loading dose is par-
ticularly important to ensure appropriate serum
concentrations of drugs.72
Regular reassessment of antibiotic therapy should oc-
cur in relation to the patient’s clinical condition. Treat-
ment should be for a minimum of 7–10 days and it is
essential that treatment is not discontinued too soon.1,22
The most recent UK CMACE report suggested a strat-
ified approach to antibiotics in sepsis (Table 7);1 antibi-
otic regimens should be altered to adapt to the
requirements of the local population and the particular
clinical situation of the patient.
In addition to starting antibiotic therapy it is essential
that any septic focus is identified and removed wherever
feasible. This may require urgent surgery and appropri-
ate imaging and surgical opinion should be undertaken
as soon as possible.
Early haemodynamic resuscitation is a key goal of
therapy.74,75 The objective is to restore adequate oxygen
delivery to peripheral tissues. It is well recorded that in
high-risk surgical patients with sepsis, early haemody-
namic optimisation before, as opposed to after, the
development of organ failure reduces mortality by
23%.76,77 In hypotensive septic patients with a serum lac-
tate >4 mmol/L volume resuscitation should be used ini-ic sepsis
ll:
axime 1–2 g 8-hourly or 6-hourly plus metronidazole 500 mg 8-
ycin 500 mg 12-hourly or clindamycin 600 mg to 1.2 g 8-hourly
waiting for microbiological advice
-hourly plus gentamicin 3–5 mg/kg daily in divided doses every
gentamicin
naerobic cover
mg to 1.2 g three or four times daily, 8-hourly is more effective
mg/kg 12-hourly for three doses, then 10 mg/kg 24-hourly or
reased efficacy and reduced nephrotoxicity.73
64 Sepsis in obstetricstially, aiming to reach the following clinical endpoints:
central venous pressure 8–12 mmHg, mean arterial pres-
sure 65 mmHg, and a urine output of 0.5 mL/kg/h. If
measurable, a central venous oxygen saturation of
>70% should be aimed for. There is no evidence to sup-
port one type of intravenous fluid over another.78 Vaso-
pressor support may be considered even before optimal
intravenous loading has been achieved.79 Transfusion of
red blood cells may be necessary if tissue oxygen delivery
still remains inadequate.80
Fluid management is difficult in sepsis and may be
particularly so in the severely ill obstetric patient: fluid
overload leading to pulmonary oedema has contrib-
uted to the deaths of some women in UK Confidential
Enquiries Reports.1 There are various reasons why the
obstetric patient may be vulnerable to fluid overload:
the physiological changes of pregnancy are such that
at term the parturient is already in a relatively volume
overloaded state; co-morbidity such as preeclampsia
may be present and uterotonic drugs that are known
to predispose to fluid retention (e.g. oxytocin) or pul-
monary oedema (e.g. carboprost) may have. Oesopha-
geal Doppler monitoring to guide intravenous fluid
therapy has recently been endorsed by the National
Institute for Clinical Health and Excellence.81
Although this report did not assess its use in obstetric
patients, the oesophageal Doppler has been used suc-
cessfully in the obstetric emergency situation,82 and it
would seem likely and appropriate that this minimally
invasive technique should become increasingly used in
obstetric practice.
Supplemental oxygen therapy is recommended even if
there is no respiratory distress. Tracheal intubation and
ventilation should be considered if the level of con-
sciousness is low or if there is hypoxia or progressive
respiratory distress.83
Necrotising fasciitis is a surgical emergency. It has
been described in association with caesarean section,84
and can present as a perineal infection after vaginal
delivery.85 It is characterized by widespread necrosis of
subcutaneous tissue and fascia and is most commonly
associated with group A streptococcal infection,
although a mixed bacterial flora including anaerobes is
often present. In the early stages it may be difficult to
distinguish between cellulitis and necrotising fasciitis.
Distinguishing features include the presence of copious
and malodorous discharge, dusky skin discolouration,
markedly severe pain and radiological or clinical evi-
dence of gas in the soft tissues.86
Role of the anaesthetist
The anaesthetist may have a pivotal role in the manage-
ment of the severely septic parturient.87 In UK practice
acute management and stabilisation of the septic obstet-
ric patient in the maternity unit, is most often conductedby the obstetric anaesthetic team. The initial multidisci-
plinary ‘golden hour’ of immediate treatment needs to
be guided by using a specially adapted sepsis bundle
written for the parturient.64 If the patient does not re-
spond rapidly and the decision is made to escalate to le-
vel-3 critical care, this transfer should be carried out by
an appropriately skilled doctor. Transfer of the critically
septic patient requires satisfactory stabilisation, rigorous
en-route monitoring and close communication with the
receiving unit. Lack of early and precise communication
between specialties is an ongoing problem with clini-
cians involved with obstetric emergencies, and the
anaesthetist is often best placed to communicate be-
tween the various teams involved.1,22
Decisions relating to the delivery of the baby are ulti-
mately the responsibility of the obstetrician, although
the obstetric anaesthetist may be able to advise on the
timing in relation to maternal resuscitation. The anaes-
thetist then has to make a decision about whether to per-
form surgery using neuraxial or general anaesthesia. It is
generally agreed that neuraxial anaesthesia is relatively
contraindicated in patients with severe sepsis. The big-
gest concerns are the supposed increased risk of epidural
abscess or meningitis. Quantifying these risks is difficult
- the white cell count increases in pregnancy and partic-
ularly during labour,88 and there is little correlation be-
tween white cell count and the presence of bacteraemia
in pregnancy.89
Epidural abscess in association with neuraxial block-
ade can occur as a result of direct introduction of micro-
organisms on the needle, via local infection at the punc-
ture site, contaminated fluids or the epidural catheter
acting as a foreign body and a nidus for infection in
the presence of bacteraemia. Spontaneous cases unre-
lated to neuraxial anaesthesia are also described and
while underlying medical conditions such as diabetes
can increase risk, epidural abscesses have also occurred
in postpartum women without risk factors and who did
not receive neuraxial block.90 The incidence in all pa-
tients admitted to hospital has been estimated at 0.2–
1.2/10 000.91 The Third National Audit Project of the
Royal College of Anaesthetists found an incidence of 1
in 47000 cases although the majority of reports occurred
in perioperative patients:92 there was only one report in
an obstetric patient. Scott and Hibbard in a retrospec-
tive review found only one case in 505000 women who
received epidural anaesthesia for vaginal delivery or cae-
sarean section.93 An incidence of 3% has been quoted in
patients who had epidural catheters inserted for chronic
pain procedures.94 Similarly there are several case re-
ports in the literature of meningitis following spinal
and epidural anaesthesia and also epidural blood
patches,95–97 but it is difficult to draw firm conclusions
from isolated reports. Common features to these reports
include difficult procedures, multiple attempts and epi-
dural catheters remaining in situ for extended periods.
D.N. Lucas et al. 65In 2004 the American Society of Regional Anesthesia
and Pain Medicine convened a Practice Advisory Panel
on the Infectious Complications Associated with Regio-
nal Anesthesia and Pain Medicine who produced a series
of practice guidelines.98,99 All patients with local or sys-
temic infection who require neuraxial anaesthesia
should be considered at risk of central nervous system
infection. The current evidence suggests that patients
with evidence of systemic infection may safely receive
spinal anaesthesia provided the patient has been com-
menced on antibiotics and shows a response to treat-
ment. Regarding epidural insertion, evidence is limited
to very small studies in women with chorioamnionitis
which suggests that it may be safe in similar circum-
stances. Only in the most unusual circumstances should
central neural blockade be performed in patients with
untreated systemic infection.
Two final points to consider in relation to neuraxial
anaesthesia and sepsis are that a septic hypotensive
patient may not tolerate the sympathetic blockade
and that coagulopathy may have developed. Ulti-
mately the decision to perform an epidural or spinal
in these circumstances must be considered on a case-
by-case basis, assessing the risk-benefit ratio for that
individual.
General anaesthesia may often be indicated and
once achieved this can facilitate initiating invasive
vascular monitoring and inotropic support, if indi-
cated. Decisions as to the reversal of general anaes-
thesia will depend on the stability of the patient. It
may be safer to first transfer the intubated, ventilated
patient under ongoing sedation to a more appropriate
environment.
Not uncommonly radiological imaging will need to
be undertaken to help identify the source of sepsis and
this should only occur in the stabilised patient. Early re-
moval of the source of sepsis is recommended whenever
possible and suitably cross-matched blood and blood
products may be required before and during surgery.
The future
Sepsis is a major cause of morbidity and mortality
worldwide and a huge amount of work has been directed
at improving the outcome of this condition. The man-
agement of sepsis in obstetric practice is likely to benefit
from this work. The UK Obstetric Surveillance System
is running a two year population-based case-control
study to investigate the incidence, associated risk factors
and management and outcomes of severe maternal sep-
sis which will provide valuable information.100 The
RCOG are due to publish their own guidelines soon.
Recommendations from the most recent UK CMACE
report emphasize the importance of early recognition
of and response to the septic obstetric patient in a
‘back-to-basics’ manner.References
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